Current overview of functions of FoxO proteins, with special regards to cellular homeostasis, cell response to stress, as well as inflammation and aging

Advances in Medical Sciences

Volumn 57, Issue 2, 2012, Pages 183-195

  Watroba, M ^a   Maslinska D ^a,b   Maslinski S ^a,c  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

^b MOSSAKOWSKI MEDICAL RESEARCH CENTRE   (Poland)

^c INSTITUTE OF RHEUMATOLOGY   (Poland)

Author keywords

Aging; Carcinogenesis; Cellular homeostasis; Degeneration; FoxO; Inflammation

Indexed keywords

BETA CATENIN; DNA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P53; REACTIVE OXYGEN METABOLITE; TRANSCRIPTION FACTOR FOXO;

ACETYLATION; AGING; APOPTOSIS; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE REGULATION; CELL CYCLE S PHASE; CELLULAR DISTRIBUTION; CELLULAR STRESS RESPONSE; DEGENERATIVE DISEASE; DIABETES MELLITUS; DNA REPAIR; DOWN SYNDROME; HOMEOSTASIS; HUMAN; HYPERTENSION; INFLAMMATION; MAMMAL CELL; OBESITY; PATHOGENESIS; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; PROTEIN SYNTHESIS; REVIEW; UBIQUITINATION;

EID: 84879596286     PISSN: 18961126     EISSN: 18984002     Source Type: Journal    
DOI: 10.2478/v10039-012-0039-1     Document Type: Review

References (91)

1. Weidinger C, Krause K, Klagge A, Karger S, Fuhrer D. Forkhead box-O transcription factor: critical conductors of cancer's fate. Endocr Relat Cancer. 2008 Dec;15(4):917-29.
2. Dijkers PF, Medema RH, Pals C, Banerji L, Thomas NS, Lam EW, Burgering BM, Raaijmakers JA, Lammers JW, Koenderman L, Coffer PJ. Forkhead transcription factor FKHR-L1 modulates cytokine-dependent transcriptional regulation of p27(KIP1). Mol Cell Biol. 2000 Dec;20(24):9138-48. (Pubitemid 32246103)
3. Reynisdóttir I, Polyak K, Iavarone A, Massagué J. Kip/Cip and Ink4 Cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-beta. Genes Dev. 1995 Aug 1;9(15):1831-45.
4. Smith EJ, Leone G, DeGregori J, Jakoi L, Nevins JR. The accumulation of an E2F-p130 transcriptional repressor distinguishes a G0 cell state from a G1 cell state. Mol Cell Biol. 1996 Dec;16(12):6965-76. (Pubitemid 26389756)
5. Ramaswamy S, Nakamura N, Sansal I, Bergeron L, Sellers WR. A novel mechanism of gene regulation and tumor suppression by the transcription factor FKHR. Cancer Cell. 2002 Jul;2(1):81-91. (Pubitemid 41043990)
6. Furukawa-Hibi Y, Yoshida-Araki K, Ohta T, Ikeda K, Motoyama N. FOXO forkhead transcription factors induce G(2)-M checkpoint in response to oxidative stress. J Biol Chem. 2002 Jul 26;277(30):26729-32. (Pubitemid 34951676)
7. Martinez-Gac L, Marqués M, Garcia Z, Campanero MR & Carrera AC. Control of cyclin G2 mRNA expression by forkhead transcription factors: novel mechanism for cell cycle control by phosphoinositide 3-kinase and forkhead. Mol Cell Biol. 2004 Mar;24(5): 2181-9. (Pubitemid 38248955)
8. Kops GJ, Medema RH, Glassford J, Essers MA, Dijkers PF, Coffer PJ, Lam EW, Burgering BM. Control of cell cycle exit and entry by protein kinase B-regulated forkhead transcription factors. Mol Cell Biol. 2002 Apr;22(7):2025-36. (Pubitemid 34224611)
9. Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS, Anderson MJ, Arden KC, Blenis J, Greenberg ME. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell. 1999 Mar 19; 96(6):857-68. (Pubitemid 29165088)
10. Modur V, Nagarajan R, Evers BM, Milbrandt J. FOXO proteins regulate tumor necrosis factor-related apoptosis inducing ligand expression. Implications for PTEN mutation in prostate cancer. J Biol Chem. 2002 Dec 6;277(49):47928-37. (Pubitemid 36159321)
11. Stahl M, Dijkers PF, Kops GJ, Lens SM, Coffer PJ, Burgering BM, Medema RM. The forkhead transcription factor FoxO regulates transcription of p27Kip1 and Bim in response to IL-2. J Immunol. 2002 May 15;168(10):5024-31. (Pubitemid 34495965)
12. Puthalakath H, Huang DC, O'Reilly LA, King SM, Strasser A. The proapoptotic activity of the Bcl-2 family member Bim is regulated by interaction with the dynein motor complex. Mol Cell. 1999 Mar 3;(3):287-96. (Pubitemid 29290669)
13. Adams JM, Cory S. The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene. 2007 Feb 26; 26(9):1324-37. (Pubitemid 46328466)
14. You H, Pellegrini M, Tsuchihara K, Yamamoto K, Hacker G, Erlacher M, Villunger A, Mak TW. FOXO3adependent regulation of Puma in response to cytokine/growth factor withdrawal. J Exp Med. 2006 Jul 10;203(7):1657-63. (Pubitemid 44036270)
15. Tang TT, Dowbenko D, Jackson A, Toney L, Lewin DA, Dent AL, Lasky LA. The forkhead transcription factor AFX activates apoptosis by induction of the BCL- 6 transcriptional repressor. J Biol Chem. 2002 Apr 19;277(16):14255-65. (Pubitemid 34968040)
16. Hollander MC, Sheikh MS, Bulavin DV, Lundgren K, Augeri-Henmueller L, Shehee R, Molinaro TA, Kim KE, Tolosa E, Ashwell JD, Rosenberg MP, Zhan Q, Fernandez- Salguero PM, Morgan WF, Deng CX, Fornace AJ Jr. Genomic instability in Gadd45a-deficient mice. Nat Genet. 1999 Oct;23(2):176-84. (Pubitemid 29455389)
17. Tran H, Brunet A, Grenier JM, Datta SR, Fornace AJ Jr, DiStefano PS, Chiang LW, Greenberg ME. DNA repair pathway stimulated by the forkhead transcription factor FOXO3a through the Gadd45 protein. Science. 2002 Apr 19;296(5567):530-4. (Pubitemid 34408672)
18. Kobayashi Y, Furukawa-Hibi Y, Chen C, Horio Y, Isobe K, Ikeda K, Motoyama N. SIRT1 is critical regulator of FOXO-mediated transcription in response to oxidative stress. Int J Mol Med. 2005 Aug;16(2):237-43.
19. Tsai WB, Chung YM, Takahashi Y, Xu Z, Hu MC. Functional interaction between FOXO3a and ATM regulates DNA damage response. Nat Cell Biol. 2008 Apr;10(4): 460-7.
20. Kops GJ, Dansen TB, Polderman PE, Saarloos I, Wirtz KW, Coffer PJ, Huang TT, Bos JL, Medema RH, Burgering BM. Forkhead transcription factor FOXO3a protects quiescent cells from oxidative stress. Nature. 2002 Sep 19;419(6904):316-21.
21. Chiribau CB, Cheng L, Cucoranu IC, Yu YS, Clempus RE, Sorescu D. FOXO3A regulates peroxiredoxin III expression in human cardiac fibroblasts. J Biol Chem. 2008 Mar 28;283(13):8211-7.
22. Gomis RR, Alarcon C, He W, Wang Q, Seoane J, Lash A & Massague J 2006 A FoxO-Smad synexpression group in human keratinocytes. Proc Natl Acad Sci. 2006 Aug 22;103(34):12747-52. (Pubitemid 44298632)
23. Allen DL, Unterman TG. Regulation of myostatin expression and myoblast differentiation by FoxO and SMAD transcription factors. Am J Physiol Cell Physiol. 2007 Jan;292(1): C188-99. (Pubitemid 46115130)
24. Van der Horst A, Burgering BM. Stressing the role of FoxO proteins in lifespan and disease. Nat Rev Mol Cell Biol. 2007 Jun;8(6):440-50. (Pubitemid 46809159)
25. Nowak K, Killmer K, Gessner C, Lutz W. E2F- 1 regulates expression of FOXO1 and FOXO3a. Biochim Biophys Acta. 2007 Apr;1769(4):244-52. (Pubitemid 46702333)
26. Imae M, Fu Z, Yoshida A, Noguchi T, Kato H. Nutritional and hormonal factors control the gene expression of FoxOs, the mammalian homologues of DAF-16. Journal of Mol Endocrinol. 2003 Apr;30(2):253-62. (Pubitemid 36592517)
27. Biggs WH, Meisenhelder J, Hunter T, Cavenee WK, Arden KC. Protein kinase B/Akt-mediated phosphorylation promotes nuclear exclusion of the winged helix transcription factor FKHR1. Proc Natl Acad Sci. 1999 Jun 22;96(13):7421-6. (Pubitemid 29299677)
28. Kashii Y, Uchida M, Kirito K, Tanaka M, Nishijima K, Toshima M, Ando T, Koizumi K, Endoh T, Sawada K, Momoi M, Miura Y, Ozawa K, Komatsu N. A member of Forkhead family transcription factor, FKHRL1, is one of the downstream molecules of phosphatidylinositol 3-kinase-Akt activation pathway in erythropoietin signal transduction. Blood. 2000 Aug 1;96(3):941-9. (Pubitemid 30616858)
29. Matsuzaki H, Ichino A, Hayashi T, Yamamoto T, Kikkawa U. Regulation of intracellular localization and transcriptional activity of FOXO4 by protein kinase B through phosphorylation at the motif sites conserved among the FOXO family. J Biochem. 2005 Oct;138(4):485-91. (Pubitemid 41703702)
30. Brunet A, Kanai F, Stehn J, Xu J, Sarbassova D, Frangioni JV, Dalal SN, DeCaprio JA, Greenberg ME, Yaffe MB. 14-3-3 transits to the nucleus and participates in dynamic nucleocytoplasmic transport. J Cell Biol. 2002 Mar 4;156(5):817-28. (Pubitemid 34839865)
31. Obsilova V, Vecer J, Herman P, Pabianova A, Sulc M, Teisinger J, Boura E, Obsil T. 14-3-3 Protein interacts with nuclear localization sequence of forkhead transcription factor FoxO4. Biochem. 2005 Aug 30;34(44):11608-17. (Pubitemid 41209097)
32. Hermeking H, Benzinger A. 14-3-3 proteins in cell cycle regulation. Semin Cancer Biol. 2006 Jun; 16(3):183-92. (Pubitemid 43810261)
33. Tsai KL, Sun YJ, Huang CY, Yang JY, Hung MC, Hsiao CD. Crystal structure of the human FOXO3a-DBD/ DNA complex suggests the effects of post-translational modification. Nucleic Acids Res. 2007;35(20):6984-94.
34. Van Der Heide LP, Jacobs FM, Burbach JP, Hoekman MF, Smidt MP. FoxO6 transcriptional activity is regulated by Thr26 and Ser184, independent of nucleocytoplasmic shuttling. Biochem J. 2005 Nov 1;391(Pt 3):623-9. (Pubitemid 41634788)
35. Yan L, Lavin VA, Moser LR, Cui Q, Kanies C, Yang E. PP2A regulates the pro-apoptotic activity of FOXO1. J Biol Chem. 2008 Mar 21;283(12):7411-20.
36. Hu MC, Lee DF, Xia W, Golfman LS, Ou-Yang F, Yang JY, Zou Y, Bao S, Hanada N, Saso H, Kobayashi R, Hung MC. IkappaB kinase promotes tumorigenesis through inhibition of forkhead FOXO3a. Cell 2004 Apr 16;117(2):225-37. (Pubitemid 38496242)
37. Hu MC, Hung MC. Role of IkappaB kinase in tumorigenesis. Future Oncol. 2005Feb;1(1):67-78.
38. Arteaga MF, Alvarez de la Rosa D, Alvarez JA, Canessa CM. Multiple translational isoforms give functional specificity to serum- and glucocorticoid-induced kinase 1. Mol Biol Cell. 2007 Jun;18(6):2072-80. (Pubitemid 46911359)
39. Huang H, Regan KM, Lou Z, Chen J, Tindall DJ. CDK2-dependent phosphorylation of FOXO1 as an apoptotic response to DNA damage. Science. 2006 Oct 13;314(5797):294-297. (Pubitemid 44571973)
40. Liu P, Kao TP, Huang H. CDK1 promotes cell proliferation and survival via phosphorylation and inhibition of FOXO1 transcription factor. Oncogene. 2008 Aug 7; 27(34):4733-44.
41. Essers MA, Weijzen S, Vries-Smits AM, Saarloos I, de Ruiter ND, Bos JL, Burgering BM. FOXO transcription factor activation by oxidative stress mediated by the small GTPase Ral and JNK. EMBO J. 2004 Dec 8;23(24):4802-12. (Pubitemid 40069710)
42. Lehtinen MK, Yuan Z, Boag PR, Yang Y, Villen J, Becker EB, DiBacco S, de la Iglesia N, Gygi S, Blackwell TK, Bonni A. A conserved MST-FOXO signaling pathway mediates oxidative-stress responses and extends life span. Cell. 2006 Jun 2;125(5):987-1001. (Pubitemid 43795191)
43. Greer EL, Oskoui PR, Banko MR, Maniar JM, Gygi MP, Gygi SP, Brunet A. The energy sensor AMPactivated protein kinase directly regulates the mammalian FOXO3 transcription factor. J Biol Chem. 2007 Oct 12; 282(41):30107-19. (Pubitemid 350035296)
44. Daitoku H, Hatta M, Matsuzaki H, Aratani S, Ohshima T, Miyagishi M, Nakajima T, Fukamizu A. Silent information regulator 2 potentiates Foxo1-mediated transcription through its deacetylase activity. Proc Natl Acad Sci. 2004 Jul 6;101(27):10042-7. (Pubitemid 38891191)
45. Perrot V, Rechler MM. The coactivator p300 directly acetylates the forkhead transcription factor Foxo1 and stimulates Foxo1-induced transcription. Mol Endocrinol. 2005 Sep;19(9):2283-98. (Pubitemid 41258099)
46. Giannakou ME, Partridge L. The interaction between FOXO and SIRT1: tipping the balance towards survival. Trends Cell Biol. 2004 Aug;14(8):408-12. (Pubitemid 39092697)
47. Brunet A, Sweeney LB, Sturgill JF, Chua KF, Greer PL, Lin Y, Tran H, Ross SE, Mostoslavsky R, Cohen HY, Hu LS, Cheng HL, Jedrychowski MP, Gygi SP, Sinclair DA, Alt FW, Greenberg ME. Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. Science. 2004 Mar 26;303(5666):2011-5. (Pubitemid 38393275)
48. Matsuzaki H, Daitoku H, Hatta M, Aoyama H, Yoshimochi K, Fukamizu A. Acetylation of Foxo1 alters its DNA-binding ability and sensitivity to phosphorylation. Proc Natl Acad Sci. 2005 Aug 9;102(32):11278-83. (Pubitemid 41153811)
49. Huang H, Regan KM, Wang F, Wang D, Smith DI, van Deursen JM, Tindall DJ. Skp2 inhibits FOXO1 in tumor suppression through ubiquitin-mediated degradation. Proc Natl Acad Sci. 2005 Feb 1;102(5):1649-54. (Pubitemid 40209222)
50. Reagan-Shaw S, Ahmad N. The role of Forkheadbox Class O (FoxO) transcription factors in cancer: a target for the management of cancer. Toxicol Appl Pharmacol. 2007 Nov 1;224(3):360-8. (Pubitemid 47575672)
51. Van der Horst A, Vries-Smits AM, Brenkman AB, van Triest MH, van den BN, Colland F, Maurice MM, Burgering BM. FOXO4 transcriptional activity is regulated by monoubiquitination and USP7/HAUSP. Nat Cell Biol. 2006 Oct;8(10):1064-73. (Pubitemid 44473601)
52. Vogt PK, Jiang H, Aoki M. Triple layer control: phosphorylation, acetylation and ubiquitination of FOXO proteins. Cell Cycle. 2005 Jul;4(7):908-13. (Pubitemid 41359756)
53. Hoppler S, Kavanagh CL. Wnt signalling: variety at the core. Jl Cell Sc. 2007 Feb 1; 120(Pt 3):385-93. (Pubitemid 46332502)
54. Almeida M, Han L, Martin-Millan M, O'Brien CA, Manolagas SC. Oxidative stress antagonizes Wnt signaling in osteoblast precursors by diverting beta-catenin from T cell factor- to forkhead box O-mediated transcription. J Biol Chem. 2007 Sep 14;282(37): 27298-305. (Pubitemid 47501978)
55. Rena G, Guo S, Cichy SC, Unterman TG, Cohen P. Phosphorylation of the transcription factor forkhead family member FKHR by protein kinase B. J Biol Chem. 1999 Jun;274(24): 17179-83.
56. Nakamura M, Ramaswamy S, Vazquez F, Signoretti S, Loda M, Sellers WM. Forkhead transcription factors are critical effectors of cell death and cell cycle arrest downstream of PTEN. Mol Cell Biol. 2000 Dec;20(23):8969-82. (Pubitemid 32245927)
57. Dijkers PF, Birgenkamp KU, Lam EWF, Shaun N, Thomas B, Lammers JWJ, Coffer PJ. FKHR-L1 can act as a critical effector of cell death induced by cytokine withdrawal protein kinase B-enhanced cell survival through maintenance of mitochondrial integrity. J Cell Biol. 2002 Jan;156(3):531-42. (Pubitemid 34839900)
58. Erol A. Systemic DNA damage response and metabolic syndrome as a premalignant state. Curr Mol Med. 2010 Apr;10(3):321-34.
59. Astanehe A, Arenillas D, Wasserman WW, Leung PC, Dunn SE, Davies BR, Mills GB, Auersperg N. Mechanisms underlying p53 regulation of PIK3CA transcription in ovarian surface epithelium and in ovarian cancer. J Cell Sci. 2008 Mar 1;121(Pt 5):664-74. (Pubitemid 351524165)
60. Chen Z, Trotman LC, Shaffer D, Lin HK, Dotan ZA, Niki M, Koutcher JA, Scher HI, Ludwig T, Gerald W, Cordon-Cardo C, Pandolfi PP. Crucial role of p53- dependent cellular senescence in supression of Pten-deficient tumorigenesis. Nature. 2005 Aug 4; 436(7051):725-30. (Pubitemid 41117277)
61. Lee C, Kim JS, Waldman T. Activated PI3K signalling as an endogenous inducer of p53 in human cancer. Cell Cycle. 2007 Feb 15;6(4):394-6. (Pubitemid 46393439)
62. Salminen A, Kaarniranta K. NF-kappaB signalling in the aging process. J Clin Immunol. 2009 Jul;29(4):397-405.
63. Guarente L. Sirtuins as potential targets for metabolic syndrome. Nature. 2006 Dec 14; 444(7121):868-74. (Pubitemid 46024994)
64. Coppe JP, Patil CK, Rodier F, Sun Y, Munoz DP, Goldstein J, Nelson PS, Desprez PY, Campisi J. Senscenceassociated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and p53 tumor supressor. PLoS Biol. 2008 Dec 2;6(12): 2853-68.
65. Webster GA, Perkins ND. Transcriptional cross talk between NF-kappaB and p53. Mol Cell Biol. 1999 May;19(5):3485-95. (Pubitemid 29193808)
66. Culmsee C, Siewe J, Junker V, Retiounskaia M, Schwarz S, Camandola S, El-Metainy S, Behnke H, Mattson MP, Krieglstein J. Reciprocal inhibition of p53 and nuclear factor-kappa B transcriptional activities determines cell survival or death in neurons. J Neurosci. 2003 Sep 17;23(24):8586-95. (Pubitemid 37158758)
67. Wang CY, Kim HH, Hiroi Y, Sawada N, Salomone S, Benjamin LE, Walsh K, Moskowitz MA, Liao JK. Obesity increases vascular senescence and susceptibility to ischemic injury through chronic activation of Akt and mTOR. Sci Signal. 2009 Mar 17;2(62):ra11.
68. Lu T, Finkel T. Free radicals and senescence. Exp Cell Res. 2008 Jun 10;314(9):1918-22.
69. Colavitti R, Finkel T. Reactive oxygen species as mediators of cellular senescence. IUBMB Life. 2005 Apr- May;57(4-5):277-81. (Pubitemid 40904255)
70. Storz P. Reactive oxygen species-mediated mitochondria-to-nucleus signaling: a key to aging and radicalcaused diseases. Sci STKE. 2006 Apr 25;2006(332):re3.
71. Haince JF, Kozlov S, Dawson VL, Dawson TM, Hendzel MJ, Lavin MF, Poirier GG. Ataxia telangiectasia mutated (ATM) signaling network is modulated by a novel poly(ADP-ribose)-dependent pathway in the early response to DNA-damaging agents. J Biol Chem. 2007 Jun 1;282(22):16441-53. (Pubitemid 47100334)
72. Maejima Y, Adachi S, Ito H, Hirao K, Isobe M. Induction of premature senescence in cardiomyocytes by doxorubicin as a novel mechanism of myocardial damage. Aging Cell. 2008 Mar;7(2):125-36. (Pubitemid 351359646)
73. Leri A, Franco S, Zacheo A, Barlucchi L, Chimenti S, Limana F, Nadal-Ginard B, Kajstura J, Anversa P, Blasco MA. Ablation of telomerase and telomere loss leads to cardiac dilatation and heart failure associated with p53 upregulation. EMBO J. 2003 Jan 2;22(1): 131-9. (Pubitemid 36091276)
74. Sandri M, Sandri C, Gilbert A, Skurk C, Calabria E, Picard A, Walsh K, Schiaffino S, Lecker SH, Goldberg AL. Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell. 2004 Apr 30;117(3): 399-412. (Pubitemid 38534545)
75. Kamei Y, Miura S, Suzuki M, Kai Y, Mizukami J, Taniguchi T, Mochida K, Hata T, Matsuda J, Aburatani H, Nishino I, Ezaki O. Skeletal muscle FOXO1 (FKHR) transgenic mice have less skeletal muscle mass, down-regulated Type I (slow twitch/red muscle) fiber genes, and impaired glycemic control. J Biol Chem. 2004 Sep 24;279(39):41114-23. (Pubitemid 39287713)
76. Nakae J, Cao Y, Oki M, Orba Y, Sawa H, Kiyonari H, Iskandar K, Suga K, Lombes M, Hayashi Y. Forkhead transcription factor FoxO1 in adipose tissue regulates energy storage and expenditure. Diabetes. 2008 Mar;57(3):563-76.
77. Blüher M, Bashan N, Shai I, Harman-Boehm I, Tarnovscki T, Avinaoch E, Stumvoll M, Dietrich A, Klöting N, Rudich A. Activated Ask1-MKK4-p38MAPK/JNK stress signaling pathway in human omental fat tissue may link macrophage infiltration to whole-body Insulin sensitivity. J Clin Endocrinol Metab. 2009 Jul;94(7):2507-15.
78. Bashan N, Dorfman K, Tarnovscki T, Harman- Boehm I, Liberty IF, Blüher M, Ovadia S, Maymon- Zilberstein T, Potashnik R, Stumvoll M, Avinoach E, Rudich A. Mitogen-activated protein kinases, inhibitory-kappaB kinase, and insulin signaling in human omental versus subcutaneous adipose tissue in obesity. Endocrinology. 2007 Jun;148(6): 2955-62. (Pubitemid 46984790)
79. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes. 2005 Jun;54(6):1615-25. (Pubitemid 40770750)
80. Zhang T, Kraus WL. SIRT1-dependent regulation of chromatin and transcription: linking NAD(+) metabolism and signaling to the control of cellular functions. Biochim Biophys Acta. 2010 Aug;1804(8):1666-75.
81. Revollo JR, Grimm AA, Imai S. The NAD biosynthesis pathway mediated by nicotinamide phosphoribosyltransferase regulates Sir2 activity in mammalian cells. J Biol Chem. 2004 Dec 3;279(49):50754-63. (Pubitemid 40017813)
82. Dandona P, Aljada A, Chaudhuri A, Mohanty P, Garg R. Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and inflammation. Circulation. 2005 Mar 22;11(11):1448-54. (Pubitemid 40396812)
83. Dandona P, Aljada A, Bandyopadhyay A. Inflammation: the link between insulin resistance, obesity and diabetes. Trends Immunol. 2004 Jan;25(1):4-7. (Pubitemid 38032801)
84. Grundy SM. Does a diagnosis of metabolic syndrome have value in clinical practice? Am J Clin Nutr. 2006 Jun;83(6):1248-51. (Pubitemid 44713050)
85. Dandona P, Aljada A, Chaudhuri A, Mohanty P, Rajesh G. A novel view of metabolic syndrome. Metab Syndr Relat Disord. 2004 Spring;2(1):2-8. (Pubitemid 39341702)
86. Kahn R. Metabolic syndrome: is it a syndrome? Does it matter? Circulation. 2007 Apr 3; 115(13):1806-11.
87. Erol A. Retrograde regulation due to mitochondrial dysfunction may be an important mechanism for carcinogenesis. Med Hypotheses. 2005;65(3):525-9. (Pubitemid 40956950)
88. Woods YL, Rena G, Morrice N, Barthel A, Becker W, Guo S, Unterman TG, Cohen P. The kinase DYRK1A phosphorylates the transcription factor FKHR at Ser329 in vitro, a novel in vivo phosphorylation site. Biochem J. 2001 May 1;355(3):597-607. (Pubitemid 32434075)
89. Wegiel J, Kaczmarski W, Barua M, Kuchna I, Nowicki K, Wang KC, Shuang YM, Frackowiak J, Mazur- Kolecka B, Silverman WP, Reisberg B, Monteiro I, de Leon M, Wisniewski T, Dalton A, Lai F, Hwang YW, Adayev T, Liu F, Iqbal K, Iqbal IG, Gong CX. The link between DYRK1A overexpression and several-fold enhancement of neurofibrillary degeneration with 3-repeat tau protein in Down Syndrome. J Neuropathol Exp Neurol. 2011 Jan;70(1):36-50.
90. Wegiel J, Gong CX, Hwang YW. The role of DYRK1A in neurodegenerative diseases. FEBS J. 2011 Jan;278(2):236-45.
91. Park J, Song WJ, Chung KC. Function and regulation of Dyrk1A: towards understanding Down Syndrome. Cell Mol Life Sci. 2009 Oct;66(20):3235-40.